Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

  1. Michael Joubert1,2,3,
  2. Benoît Jagu1,
  3. David Montaigne4,
  4. Xavier Marechal4,
  5. Angela Tesse1,
  6. Audrey Ayer1,
  7. Lucile Dollet1,
  8. Cédric Le May1,
  9. Gilles Toumaniantz1,
  10. Alain Manrique3,
  11. Flavien Charpentier1,
  12. Bart Staels4,
  13. Jocelyne Magré1,
  14. Bertrand Cariou5 and
  15. Xavier Prieur1⇑
  1. 1L’Institut du Thorax, INSERM, CNRS, Université de Nantes, Nantes, France
  2. 2Endocrinologie, CHU Caen, Caen, France
  3. 3EA 4650, UNICAEN, GIP Cyceron, Caen, France
  4. 4Universite Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011–European Genomic Institute for Diabetes, Lille, France
  5. 5L’Institut du Thorax, INSERM, CNRS, Université de Nantes, CHU Nantes, Nantes, France
  1. Corresponding author: Xavier Prieur, xavier.prieur{at}univ-nantes.fr.
Diabetes 2017 Apr; 66(4): 1030-1040. https://doi.org/10.2337/db16-0733
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure. T2DM is associated with altered cardiac energy metabolism, leading to ectopic lipid accumulation and glucose overload, the exact contribution of these two parameters remaining unclear. To provide new insight into the mechanism driving the development of diabetic cardiomyopathy, we studied a unique model of T2DM: lipodystrophic Bscl2−/− (seipin knockout [SKO]) mice. Echocardiography and cardiac magnetic resonance imaging revealed hypertrophic cardiomyopathy with left ventricular dysfunction in SKO mice, and these two abnormalities were strongly correlated with hyperglycemia. Surprisingly, neither intramyocardial lipid accumulation nor lipotoxic hallmarks were detected in SKO mice. [18F]Fludeoxyglucose positron emission tomography showed increased myocardial glucose uptake. Consistently, the O-GlcNAcylated protein levels were markedly increased in an SKO heart, suggesting a glucose overload. To test this hypothesis, we treated SKO mice with the hypoglycemic sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and the insulin sensitizer pioglitazone. Both treatments reduced the O-GlcNAcylated protein levels in SKO mice, and dapagliflozin successfully prevented the development of hypertrophic cardiomyopathy. Our data demonstrate that glucotoxicity by itself can trigger cardiac dysfunction and that a glucose-lowering agent can correct it. This result will contribute to better understanding of the potential cardiovascular benefits of SGLT2 inhibitors.

Introduction

Type 2 diabetes mellitus (T2DM) is a well-recognized independent risk factor for heart failure (HF) (1,2). Whereas the prevalence of HF in the general population is 1–4%, it reaches ∼12% in patients with T2DM (3). In 1972, Rubler et al. (4) reported a specific diabetes-associated cardiac injury called diabetic cardiomyopathy. This cardiomyopathy is defined by ventricular dysfunction occurring without coronary disease or hypertension (1,5). Diabetic cardiomyopathy is also characterized by left ventricular (LV) hypertrophy, diastolic dysfunction, and myocardial fibrosis (1,5).

A large body of work indicates that diabetic cardiomyopathy is associated with altered cardiac energy metabolism (6). Indeed, in obese patients with T2DM, heart lipid uptake is increased (7). Several studies support that free fatty acid (FFA) accumulation leads to the increased production of diacylglycerol (DAG), ceramides, and reactive oxygen species (ROS), affecting cardiac insulin sensitivity (8,9) and cardiac contractility (6,10,11).

On the other hand, hyperglycemia and glucose overload have been involved in cardiac hypertrophy and dysfunction in the context of T2DM and obesity (12). The diabetic heart is simultaneously characterized by impaired insulin-stimulated glucose uptake (13) and obvious signs of glucose overload, such as ROS and advanced glycation end product (AGE) production as well as hexosamine pathway chronic activation (12,14). Interestingly, when comparing obese patients with and without diabetes, we previously demonstrated that hyperglycemia per se plays a central role in the impaired cardiac mitochondrial activity associated with myocardial contractile dysfunction (15).

The exact contribution of lipotoxicity and glucotoxicity remains unclear. Most rodent studies have been performed in obese animals, and it remains difficult, in this setting, to distinguish the respective contribution of obesity, insulin resistance, and hyperglycemia. To provide new insight into the mechanism driving the development of diabetic cardiomyopathy, we aimed to use a unique nonobese model of diabetes: the lipodystrophic Bscl2−/− (seipin knockout [SKO]) mouse model.

Berardinelli-Seip congenital lipodystrophy (BSCL) is characterized by an almost complete lack of adipose tissue from birth or early infancy. In ∼50% of the cases, BSCL is the result of mutations in BSCL2 encoding the protein Seipin (16). BSCL is associated with major metabolic complications, such as insulin resistance progressing to overt diabetes, hypertriglyceridemia, and liver steatosis (17). In addition, cardiomyopathy frequently occurs in patients with BSCL (18). Most patients have concentric LV hypertrophy, equally split into mild, moderate, and severe, often associated with diastolic dysfunction but generally with preserved systolic function. About half of the patients (54%) display abnormal electrocardiogram (ECG) with prolonged QT intervals and nonspecific T-wave abnormalities (18). It is not clear yet whether this cardiomyopathy is associated with ectopic myocardial lipid accumulation (19–21). Thus, the phenotype of lipodystrophic cardiomyopathy is poorly characterized, and the underlying molecular mechanism remains unknown.

We and others (22–24) have previously shown that SKO mice are severely lipodystrophic and display insulin resistance, diabetes, and massive liver steatosis. In this study, we performed cardiac phenotyping of the SKO mice, and we used dapagliflozin treatment, a sodium–glucose cotransporter 2 (SGLT2), and the insulin sensitizer pioglitazone to reverse the hyperglycemia that appears to be central to the development of cardiomyopathy in these animals.

Research Design and Methods

Animals, Physical Activity, and Dapagliflozin Treatment

SKO mice were generated as previously described (24) and housed at 21°C with a 12:12-h light/dark cycle with free access to food and water. The experimental procedures were approved by the regional ethics committee (Comités d'éthique en expérimentation animale, Pays de la Loire, France) according to Directive 2010/63/EU of the European Union. For physical activity assessment, the mice were submitted to graduated aerobic exercise training, performed on a motor treadmill (slop 0°) over 4 weeks. Dapagliflozin, an SGLT-2 inhibitor, was obtained from Interchim (Montluçon, France) and added to the drinking water at a concentration of 1 mg/kg for 8 weeks. Pioglitazone (Interchim) was added to the diet at a concentration of 300 mg/kg (45 mg/kg/day) for 8 weeks. Mice started the treatment at 6 weeks of age. All animals were killed in a random-fed state.

ECG

ECGs were performed as previously described (25). Briefly, under isoflurane anesthesia, a six-lead ECG was recorded with 25-gauge subcutaneous electrodes on a computer through an analog-digital converter (IOX 1.585; EMKA Technologies, Paris, France) for monitoring and offline analysis (ECG Auto v3.2.0.2; EMKA Technologies).

Echocardiography

Mice were anesthetized with isoflurane, and two-dimensional echocardiography was performed on mice using Vivid 7 Dimension ultrasonography (GE Healthcare) with a 14-MHz transducer. The Doppler-derived mitral deceleration time, the early diastolic (E), late diastolic (A), and E/A ratio were obtained to assess diastolic dysfunction.

Cardiac Magnetic Resonance and Cardiac Function Postanalysis

Cardiac magnetic resonance (CMR) was performed using a 7-Tesla Bruker Pharmascan magnetic resonance imager (Bruker Biospin, Ettlingen, Germany) interfaced with a dedicated small-animal electrocardiographic and respiratory triggering system (SA Instruments). Ventricular function and wall deformation were assessed using a triggered cine FLASH sequence and tagged CMR frames, respectively, as previously described (26).

Micro–Positron Emission Tomography Computed Tomography

Mice were fasted for 2 h and then anesthetized with isoflurane (1.5–3%) in an oxygen/nitrous oxide mixture (0.6 L/min) via spontaneous breathing. A 10-min computed tomography scan was first acquired for subsequent attenuation correction and anatomical identification. Then, a 60-min positron emission tomography (PET) acquisition was initiated, along with 10-s tail vein injection of [18F]fludeoxyglucose (FDG) or [11C]acetate (15–20 MBq in 50–100 µL for both radiolabeled markers). For myocardial glucose uptake (MGU; mmol/g/min) and myocardial VO2 (µmol/100 g/min) analysis, [18F]FDG and [11C]acetate PET acquisition data were sorted in 24 and 56 dynamic frames, respectively, secondarily analyzed, and quantified with Carimas software (Turku PET Center, Turku, Finland) using Patlak kinetic analysis and a one-tissue compartment model as described elsewhere (27).

In Vivo Lipid Metabolism

[3H]VLDL was produced as previously described (24). Wild-type (WT) and SKO mice were anesthetized with a xylazine/ketamine/PBS (1:1:8) solution and received 100,000 cpm [3H]VLDL. The mice were killed, and the hearts were washed in cold PBS 5 min after injection. The tissues were digested with Solvable (PerkinElmer, Courtaboeuf, France), and the radioactivity was counted.

Insulin Signaling

Twelve-week-old SKO and WT mice were fasted for 2 h, and a single dose of 0.75 IU/kg human recombinant insulin (Umuline rapide; Eli Lilly, Suresnes, France) was administered by intravenous injection. The mice were killed 5 min after injection, and the hearts were collected and washed in PBS.

Membrane Isolation, Western Blot, ROS Production, and RNA Analysis

Membrane isolation of heart lysates was performed by ultracentrifugation (75 min at 110,000 × g), and the pellets were resuspended in solubilization buffer (50 mmol/L Tris [pH 7.4], 100 mmol/L NaCl, 50 mmol/L LiCl, 5 mmol/L EDTA, 0.5% Triton X-100, 0.5% deoxycholic acid, and 0.05% SDS). For Western blot analyses, we used phospho–Ser473-AKT/AKT, phospho–Thr172–AMP kinase (AMPk)/AMPk, FOXO1, and GLUT1 antibodies from Cell Signaling Technology; SERCA2, Ser16-P-phospholamban (PLN), and PLN antibodies were from Santa Cruz Biotechnology; GLUT4 and Tubulin antibodies from Sigma-Aldrich; and an O-GlcNAc Western blot kit from Thermo Fisher Scientific. For O-GlcNAcylated protein isolation, 750 µg lysates was incubated with wheat germ agglutinin (Sigma-Aldrich) agarose conjugate and then analyzed by Western blot. The AGEs were quantified using the oxiSelect AGE competitive ELISA (Cell Biolabs), and ROS production was measured by incubating heart lysates with dichlorodihydrofluorescein diacetate (Life Technologies) for 30 min at 37°C as previously described (28). RNA expression was analyzed as previously described (24).

Tissue Lipid Extraction and Measurement

Triglyceride (TG) measurement was performed using a colorimetric assay after cyclohexane/isopropanol (3:2, volume for volume) extraction. For ceramide measurement, samples were analyzed using a 1290 UPLC system coupled to a G6460 triple quadripole spectrometer (Agilent Technologies) using MassHunter software for data acquisition and analysis. For neutral lipids, 1 mL lipid extract was analyzed by gas-liquid chromatography on a FOCUS Thermo Electron system (Thermo Fisher Scientific) using Zebron-1 Phenomenex fused silica capillary columns (29).

Evaluation of Ex Vivo Myocardial Function

Freshly excised mouse hearts were immediately mounted onto a Langendorff apparatus, as previously described (30). Briefly, hearts were perfused in 0.7, 1.4, or 2.5 mmol/L Ca2+ using Krebs-Henseleit bicarbonate buffer supplemented with two different energetic substrates (i.e., glucose [11 mmol/L] alone or glucose [11 mmol/L] in the presence of octanoate [1.5 mmol/L]). The oxygen partial pressure was measured in the coronary perfusate and effluent using specific electrodes to calculate the myocardial O2 uptake (in µL · min−1 · g−1).

Statistical Analysis

All data are reported as the mean ± SEM. Data sets were analyzed for statistical significance using a nonparametric Mann–Whitney U test, Kruskal Wallis, or two-way ANOVA analysis when specified.

Results

SKO Mice Display Hypertrophic Cardiomyopathy With Diastolic Dysfunction

As previously described (24), 10-week-old SKO mice are hyperglycemic, insulin-resistant, mildly hypotriglyceridemic, and normocholesterolemic (Supplementary Fig. 1). Therefore, we performed cardiac phenotyping in WT and SKO mice from 10–24 weeks of age. As differences between both genotypes were quite stable with aging (data not shown), we present in this study the data from 14-week-old animals. The ratio between heart weight and body weight (HW/BW) (Fig. 1A) as well as between heart weight and tibias length (Supplementary Fig. 1E) were both increased in SKO compared with WT mice. ECG showed significant prolonged QT interval duration in SKO versus WT animals (Table 1), whereas the heart rate was similar in both groups (Fig. 1B). On Doppler flow analysis, LV diastolic function parameters were markedly affected in SKO mice: the E/A ratio was increased, and both the deceleration time and the isovolumetric filling time were increased (Fig. 1C–F). Consistently, CMR imaging highlighted an increased diastolic wall thickness in SKO mice (Fig. 1G) despite a normal end diastolic volume (EDV) (Fig. 1H). Right ventricular volumes and function were normal (data not shown). In addition, SKO mice exhibited a mild ejection fraction (EF) decrease (52 vs. 64% in WT animals) (Fig. 1I) and a blunted longitudinal strain (Fig. 1J). Longitudinal strain correlated positively with EF (Fig. 1K) and negatively with end diastolic wall thickness (EDW) (Fig. 1L), highlighting the relationship among LV hypertrophy, wall deformation abnormalities, and altered EF. Finally, correlations were found among random-fed mean plasma glucose, EDW, and EF, with the most hyperglycemic animals displaying the thickest LV walls and the lowest EFs (Fig. 1M and N).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

SKO mice display hypertrophic cardiomyopathy with systolic and diastolic dysfunction. Cardiac phenotyping of 14-week-old WT (white bars) and SKO (black bars) mice was investigated as described in research design and methods. Ratio of HW (g) to BW (g) (A) and echocardiography Doppler flow analysis in WT and SKO mice (n = 8/group): heart rate (B), representative images (C), E/A ratio (D), deceleration time (E), and isovolumetric relaxation (F). CMR analysis in SKO (n = 12) and WT (n = 10) mice: EDW (G), EDV (H), EF (I), and longitudinal strain (J). Correlations using CMR parameters: EF to longitudinal strain (K), EDW to longitudinal strain (L), EDW to random-fed glycemia (M), and EF to random-fed glycemia (N). Significant differences between WT and SKO mice are represented as follows: *P < 0.05; **P < 0.01; ***P < 0.001.

View this table:
  • View inline
  • View popup
Table 1

ECG characteristics of WT and SKO mice

Absence of Lipotoxic Profile in the Heart of SKO Mice

As ectopic lipid deposition and lipotoxicity have been extensively described in diabetic cardiomyopathy, we studied cardiac lipid metabolism in SKO mice. Previously, using radiolabeled TG-rich lipoproteins, we demonstrated elevated TG uptake and a massive ectopic lipid deposition in SKO liver in vivo (24). Using the same methodology, we showed in this study that cardiac TG uptake was similar in SKO and WT mice (Fig. 2A). Cardiac lipidomic profiles showed similar TG and ceramide levels in both SKO and WT animals (Fig. 2B and C), and DAG levels were only modestly reduced in the SKO heart (Fig. 2D). In addition, we did not observe any change in the expression levels of the procatabolic nuclear receptor peroxisome proliferator–activated receptor α or of its target genes involved in FFA oxidation in SKO mice (Supplementary Fig. 2A). These data suggest that the seipin-deficient heart unexpectedly exhibits neither a lipotoxic profile nor a major impairment in lipid metabolism.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Energy metabolism in SKO mice. A: 3H-palmitate–labeled TRL uptake was evaluated 5 min after injection by counting total amount of radioactivity in the heart in 14-week-old WT (white bars) and SKO (black bars) mice (n = 6/group). Total intracardiac TG (B), ceramides (C), and DAG (D) levels were measured in heart from 12-week-old WT and SKO mice (n = 6/group). E: Insulin signaling: 12-week-old WT and SKO mice were fasted for 2 h, then received a 0.75 IU/kg dose of insulin intravenously, and killed 5 min after (n = 7 insulin-injected mice and 3 saline-injected mice). The activation of AKT was measured by Western blot on heart lysates. Representative Western blots are shown, with quantification expressed as fold stimulation by insulin of the activated/phosphorylated-to-total protein ratio. F: Protein expression of GLUT4 and GLUT1 were determined by Western blot in heart lysates from 14-week-old WT and SKO mice. GAPDH and transferrin receptor were used as housekeeping protein respectively for total extract and membrane fraction (n = 8/group). [18F]FDG or [11C]acetate micro-PET/computed tomography were performed to measure glucose uptake (G) and oxygen consumption (H) (n = 7 or 4/5 WT/KO mice per group, respectively, for oxygen consumption). I: Ex vivo oxygen consumption evaluated with heart mounted in Langendorff setup as described in research design and methods. J: The AMPk activation levels have been evaluated by Western blot. Tubulin was used as an index of the protein loading. Significant differences between WT and SKO mice are represented as follows: *P < 0.05; **P < 0.01; ***P < 0.001.

Insulin Resistance Coexists With Increased Glucose Uptake in the SKO Heart

As insulin resistance and chronic exposure to hyperglycemia are also involved in the pathophysiology of diabetic cardiomyopathy, we assessed the insulin sensitivity and glucose uptake of the SKO heart. The insulin-induced phosphorylation of AKT was blunted by 70% in the hearts of SKO compared with WT mice (Fig. 2E). Consistently, in the fed state, the total and membrane GLUT4 protein levels were 50 and 40% lower, respectively, in SKO animals (Fig. 2F). GLUT4 mRNA tended to be lower in SKO, but this trend was not significant (Supplementary Fig. 2B). The GLUT1 protein (Fig. 2F) and mRNA levels (Supplementary Fig. 2B) were comparable in both genotypes. Using [18F]FDG PET scan, a marked increase in in vivo MGU was found in SKO hearts (Fig. 2G). To evaluate the fate of the glucose, we used [11C]acetate PET scan–monitored oxidation to model oxygen consumption (31–33). Our data revealed a 30% decrease in heart oxygen consumption, suggesting a decrease of all oxidative metabolism, including glucose (Fig. 2H). This latter result was further confirmed using an ex vivo–perfused heart setup, with a significant reduction of oxygen consumption in SKO hearts whether they were supplied with glucose or glucose plus octanoate (Fig. 2I). AMPk plays a central role in energetic substrate catabolism and oxygen consumption regulation. In accordance with a defect in energetic substrate utilization, a 60% decrease in phosphorylated AMPk was observed in SKO heart lysates (Fig. 2J). However, phosphorylation levels of the acetyl-coA carboxylase, one AMPk target, were not significantly decreased in SKO samples (data not shown). Together, these data demonstrate that in SKO hearts, despite marked insulin resistance, glucose uptake is elevated but oxygen consumption is reduced.

Chronic Activation of the Hexosamine Pathway Leads to Cardiac Molecular Alterations in the SKO Heart

Because glucose uptake was increased in SKO hearts, we tested different pathways that are classically activated by glucose overload in the heart. First, we observed no change in ROS production in AGE or p47-phox plasma membrane levels in SKO mice compared with WT mice (Supplementary Fig. 3). Second, we assessed the hexosamine biosynthetic pathway (HBP), which leads to the covalent addition of O-GlcNAc residues on various cellular proteins. The o-GlcNAcylated protein levels measured by Western blot were increased by 2.5-fold in SKO mice compared with WT mice (Fig. 3A). As chronic HBP activation has been previously shown to alter insulin signaling (34), we isolated O-GlcNAcylated protein using wheat germ agglutinin and analyzed these protein samples by Western blot. Importantly, the O-GlcNAcylated level of the transcription factor FOXO1, a key player in insulin sensitivity, was twofold increased, whereas its total level remains stable (Fig. 3B). In contrast, O-GlcNAcylated level of AKT was unaltered in SKO heart. In addition, the phosphorylation level of PLN, a regulator of the endoplasmic reticulum calcium pump SERCA2a, was markedly blunted in SKO hearts, whereas SERCA2 levels tended to be marginally lower in SKO heart samples (Fig. 3C). Finally, in SKO hearts, the myosin heavy chain (MHC) β/α ratio was threefold increased (Fig. 3D), and the number of positive cells in TUNEL staining was increased by 50% (Fig. 3E). Notably, no sign of fibrosis was found in SKO mouse hearts (Supplementary Fig. 3D). Together, these data demonstrate that activation of the hexosamine pathway by glucose overload is associated with molecular signs of cardiac dysfunction in SKO mice.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Accumulation of O-GlcNAcylated protein and cardiac molecular remodeling. O-GlcNAcylated protein levels (A), O-GlcNAcylated FOXO1 levels (B), SERCA2a levels, and Ser-PLN (Pser. PLN) phosphorylation levels (C) have been evaluated by Western blot. D: MHC isoform were evaluated by quantitative PCR. E: Apoptosis was evaluated by TUNEL staining. Significant differences between WT and SKO mice are represented as follows: **P < 0.01.

Dapagliflozin Improves SKO Mouse Heart Function by Limiting Cardiac Glucose Overload

As cardiac parameters were strongly correlated with plasma glucose levels, we hypothesized that targeting hyperglycemia might correct the cardiac dysfunction observed in SKO mice. To that purpose, we used the SGLT2 inhibitor dapagliflozin, which reduces hyperglycemia by increasing glycosuria. Six-week-old SKO mice were treated for 8 weeks with 1 mg/kg dapagliflozin. Dapagliflozin treatment massively increased glycosuria (Supplementary Fig. 4A), normalized plasma TG levels (Supplementary Fig. 4B), and limited hyperglycemia (Supplementary Fig. 4C), but had no effect on insulin sensitivity, liver steatosis, or body weight (Supplementary Fig. 4D–F). The HW/BW ratio displayed a nonsignificant trend to be reduced (Supplementary Fig. 4G). Echocardiography and CMR imaging analyses revealed that dapagliflozin improved the E/A ratio, decreased the isovolumetric relaxation time, reduced the deceleration time, and normalized the EDW as well as the EF (Fig. 4A–F). Finally, we tested whether the normalization of random-fed glycemia by dapagliflozin decreased the cardiac molecular consequences of glucose overload. Interestingly, dapagliflozin-treated SKO mice had significantly lower total levels of O-GlcNAcylated proteins and specifically the O-GlcNAcylated FOXO1 form as compared with untreated SKO mice (Fig. 4G and H). Moreover, the activation state of PLN was normalized, and the phosphorylation level of AMPk was also increased with dapagliflozin (Fig. 4I). These results suggest that dapagliflozin partly corrected cardiac dysfunction by decreasing the glucose overload and the subsequent hexosamine pathway activation.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Dapagliflozin improves SKO heart function by limiting cardiac glucose overload. Six-week-old SKO mice were treated with dapagliflozin (1 mg/kg) for 8 weeks. Echocardiography Doppler flow analysis was performed: E/A ratio (A), isovolumetric relaxation (B), and deceleration time (C). White bars represent WT mice (n = 8), black bars represent nontreated SKO mice (n = 13), and gray bars represent dapagliflozin-treated SKO mice (KO+DAPA; n = 7). CMR analysis performed in SKO (black bars) and KO+DAPA (gray bars) mice and compared with previously obtained data from WT mice: EDW (D), EF (E), and EDV (F). Total O-GlcNAcylated protein levels (G), FOXO1 O-GlcNAcylated protein levels (H), and AMPk activation and PLN phosphorylation levels (I) evaluated by Western blot. Pser.PLN, phospho-Ser-PLN. Significant differences between WT and SKO mice are represented as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Significant differences between SKO control and KO+DAPA were represented as follows: #P < 0.05; ##P < 0.01; ###P < 0.001.

Pioglitazone Lowers Glucose Overload but Only Partially Improves Cardiac Function

To further investigate the link between glucose overload and cardiac dysfunction, we used the insulin sensitizer pioglitazone as an alternative hypoglycemic drug. We previously published that pioglitazone treatment increases adipose tissue mass, insulin sensitivity, and random-fed hyperglycemia in SKO mice (24) (Supplementary Fig. 5A and B). Regarding the effect on cardiac function, we first noticed that pioglitazone increased the HW/BW ratio (Supplementary Fig. 5D). Cardiac echography and magnetic resonance imaging exams showed that pioglitazone treatment improved E/A ratio, deceleration time, and EDW in SKO treated as compared with SKO control mice (Fig. 5A, C, and D). In contrast, isovolumetric relaxation time was unchanged, and EF tended to be reduced, even though this decrease did not reach significance (Fig. 5B and E). Consistent with its hypoglycemic action, pioglitazone reduced the HBP pathway activation and the O-GlcNAcylated FOXO1 level (Fig. 5G and H). However, the improvements of AMPk and PLN activation did not reach statistical significance, despite a strong trend (Fig. 5I). Altogether, these data confirm that glucose-lowering agents protect SKO mice from glucotoxicity, but with pioglitazone, the cardiac dysfunction is only partially corrected compared with dapagliflozin.

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Pioglitazone lowers glucose overload but only partially improves cardiac function. Six-week-old SKO mice were treated with pioglitazone-enriched diet (300 mg/kg) for 8 weeks. Echocardiography Doppler flow analysis was performed: E/A ratio (A), isovolumetric relaxation (B), and deceleration time (C). White bars represents WT mice (n = 8), black bars represent nontreated SKO mice (n = 14), and gray bars represent pioglitazone-treated SKO mice (KO PIO; n = 8). CMR analysis performed in SKO (black bars) and KO PIO (gray bars) mice and compared with previously obtained data from WT mice: EDW (D), EF (E), and EDV (F). Total O-GlcNAcylated protein levels (G), FOXO1 O-GlcNAcylated protein levels (H), and AMPk activation and PLN phosphorylation levels (I) evaluated by Western blot. PSer-PLN, phospho-Ser-PLN. Significant differences between WT and SKO mice are represented as follows: *P < 0.05; **P < 0.01; ***P < 0.001. Significant differences between SKO control and KO PIO were represented as follows: #P < 0.05; ##P < 0.01.

Discussion

In this study, we performed for the first time a complete cardiac phenotyping of SKO mice. We showed that SKO mice exhibit LV hypertrophy, along with diastolic/systolic dysfunction and prolonged QT intervals. Whereas no signs of lipid accumulation or lipotoxicity were observed, we report an alteration in glucose metabolism in the SKO heart, with increased glucose uptake and chronic hexosamine pathway activation. The SGLT2 inhibitor dapagliflozin, and in a lesser extent the insulin sensitizer pioglitazone, alleviates the glucose overload burden, leading to a marked reduction in the O-GlcNAcylated protein levels and an improvement of the cardiac phenotype.

In our rodent model of lipodystrophy, cardiac phenotyping revealed a decreased E/A ratio and an increased isovolumetric filling time, which are both signs of decreased heart compliance, leading to diastolic dysfunction. Consistently, the LV was found to be hypertrophic and stiff, as reflected by increased EDW along with an increase in heart mass and by blunted longitudinal strain.

Regarding the mechanisms involved in the associated heart disease, we first asked the question of whether a cardiomyocyte-autonomous effect of seipin deficiency existed. Seipin is expressed at very low levels in the heart of WT animals, and we also report that the β/α MHC ratio, a marker of pathological cardiac remodeling, was comparable between 6-week-old SKO mice, which were normoglycemic at this time, and WT mice (data not shown). Conversely, at 10 weeks of age, when the hyperglycemic phenotype arose, the β/α MHC ratio was elevated, and the first cardiac imaging abnormalities (decrease in E/A ratio) began to appear in SKO mice. The positive correlation between random-fed glycemia and cardiac abnormalities reinforce our hypothesis that systemic energy metabolism has a deleterious impact on cardiac function. The improvement of the cardiac phenotype with an antihyperglycemic drug is also consistent with this insight.

Lipotoxicity has been largely involved in diabetic cardiomyopathy (9,11), and we have previously shown that SKO mice display massive hepatic ectopic lipid deposition and increased hepatic triacylglycerol-rich lipoprotein (TRL) uptake (24). Surprisingly, we did not see any changes in TRL uptake or intracardiac lipid levels (TG and ceramides) in the SKO heart. This finding is consistent with several autopsy reports that did not show ectopic lipid deposition in the hearts of patients with BSCL (19,20). Overall, the SKO mouse is not a model for heart steatosis and lipotoxicity-induced cardiac dysfunction.

As glucotoxicity has also been implicated in T2DM-associated cardiac dysfunction (14,15), we studied carbohydrate metabolism in SKO hearts. Using [18F]FDG PET imaging, we established that SKO hearts displayed increased MGU compared with WT hearts. Literature is quite puzzling and heterogeneous regarding heart glucose uptake in diabetic animals. In one study, Zucker diabetic fatty rats displayed lower glucose uptake under hyperinsulinemic-euglycemic clamp conditions compared with lean rats (35). In another study, Zucker diabetic fatty rats were fasted for 6 h, and glucose uptake PET monitored was found to be unaffected, with a trend toward an increase (33). Nutritional status obviously affects glucose uptake, and in our case, the glucose uptake assay was performed after a short 2-h fasting period to avoid major hyperglycemia that would alter PET analysis. We also avoided longer fasting, which has been previously shown to alter SKO mouse insulin sensitivity (36). In our conditions, compared with WT animals, SKO mice are massively hyperinsulinemic (23,24,37). This latter point, along with hyperglycemia, probably explains why MGU is increased in vivo despite strong insulin resistance. A similar result was obtained by Kaczmarczyk et al. (38) in GLUT4 partially deficient C57BL/6 mice. Despite a 50% decrease in GLUT4 levels compared with WT animals, these mice presented a higher baseline MGU, related to their hyperinsulinemic state. Thus, we consider that, in our setting, PET measurement of glucose uptake appropriately represents the physiological balance among cardiac insulin resistance, hyperinsulinemia, and hyperglycemia and realistically reflects the entry of glucose into cardiomyocytes. As noted, the discrepancy between the lower GLUT4 protein levels and the unchanged mRNA levels was unexpected, as, in most T2DM mice models, both are concomitants (39). Interestingly, using [11C]acetate measurement, we demonstrated that oxygen consumption was decreased in SKO hearts. When entering the cell, [11C]acetate is quickly metabolized into acetyl-CoA and then is usually catabolized in the Krebs cycle to produce ATP (40). Our data clearly indicate that the Krebs cycle activity is low in SKO mice but do not determine whether FFA or glucose oxidation is primarily affected. The ex vivo data, in isolated hearts in the presence of glucose only, confirmed that glucose oxidation is deficient in SKO hearts. This would be consistent with a large body of work demonstrating that glucose oxidation is impaired in the diabetic heart (6,33,41,42). In addition, the decreased AMPk activity in SKO hearts is consistent with altered aerobic catabolism, given that AMPk is known to promote FFA and glucose cardiac oxidation (43). Interestingly, the TG levels and the expression levels of the main genes involved in FA oxidation were not altered in SKO mice, which supports the hypothesis that the alteration occurs mainly in glucose oxidation.

We tried to highlight how glucose overload may contribute to cardiac dysfunction. Several publications have demonstrated that glucotoxicity induces oxidative stress (14,41), but using several methods, we found no oxidative stress in SKO hearts. We next investigated the involvement of the other well-known glucotoxic pathway, the HBP (44). Indeed, we found a marked increase in O-GlcNAcylated protein levels in the SKO heart, and we interpreted this finding as a clear sign of glucose overload. The HBP pathway is activated in vitro and in vivo in the context of hyperglycemia and diabetes (44). Several studies have sought to elucidate whether HBP activation has a direct causal impact on cardiac dysfunction. Indeed, pharmacological inhibition of the HBP in db/db cardiomyocytes attenuated hypertrophic signaling (45). Hyperglycemia has been shown to alter the β/α MHC ratio both ex vivo and in vivo. The increase of uridine diphosphate N-acetyl glucosamine production, the main metabolite of the HBP pathway, is suspected to be involved in the overexpression of the β form of the MHC (46), a phenomenon that could explain the increased ratio reported in SKO mice. Chronic activation of the HBP by glucose overload has also been shown to alter calcium signaling and PLN phosphorylation levels (47). Consistently, PLN Ser phosphorylation levels were decreased in SKO mice. In addition, dysregulation of O-GlcNAcylation alters mitochondrial function, oxygen consumption, and ATP synthesis (48). Thus, increased O-GlcNAcylated protein levels would alter mitochondrial function, contributing to the reduced oxygen consumption in SKO hearts.

We specifically highlighted in this study the increased O-GlcNAcylated levels of FOXO1. This is particularly interesting for two main reasons. Firstly, FOXO1 O-GlcNAcylation increases its activity (49), and this activation has been suggested to be a key mediator of glucotoxicity in different organs (50). Secondly, FOXO1 has been involved in metabolically induced cardiac dysfunction, especially insulin resistance, and FOXO1 knockdown appears to be protective in a model of diet-induced cardiomyopathy (51). Our work shows for the first time that FOXO1 O-GlcNAcylation is associated with heart insulin resistance and cardiac dysfunction. Together, these data lead us to hypothesize that in our model, glucose overload is the main trigger of cardiac dysfunction and that chronic HBP activation is a central mechanism in glucose-adverse effects.

To test this hypothesis, we used two hypoglycemic agents: the SGLT2 inhibitor dapagliflozin and the insulin sensitizer pioglitazone. In SKO mice, pioglitazone reduce glycemia through insulin-sensitivity enhancement (24), whereas dapagliflozin does not improve the insulin resistance. Both treatments lowered glycemia and reversed the HBP chronic activation, including the increase in O-GlcNAcylated FOXO1 levels, suggesting an antiglucotoxic effect. In term of cardiac function, SKO mice treated with dapagliflozin presented a decrease in ventricular wall hypertrophy and an improvement of both diastolic and systolic function. In contrast, pioglitazone corrected only partially the cardiac dysfunction in SKO mice, improving the E/A ratio and ventricular wall hypertrophy, but with no effect on the EF and the isovolumetric relaxation time. Of note, pioglitazone induced an increase of the HW/BW ratio and a trend to increase the EDV. Therefore, despite a similar antiglucose overload action, these treatments act differently because of either a deleterious side effect of pioglitazone or an additional beneficial effect of dapagliflozine and potentially by a combination of both. Thiazolidinediones have been described to induce cardiac hypertrophy through volume expansion (52). This is further supported by a large meta-analysis showing that the use of pioglitazone was associated with increased risk of nonfatal chronic HF requiring hospitalization (53). In striking contrast, SGLT2 inhibitors exert osmotic diuretic and natriuretic effects contributing to plasma volume contraction (54). In addition, a recent study suggests that empagliflozin, another SGLT2 inhibitor, increases the production of ketone bodies that are more easily used by the heart (55).

In absence of steatosis and fibrosis, the origin of cardiac hypertrophy remains poorly understood in our model. Chronic activation of the HBP in the context of diabetes is tightly correlated with cardiac hypertrophy with several transcription factors regulating prohypertrophic genes being activated (56). However, dapagliflozin only tends to lower the HW/BW ratio, suggesting that either the reduction of the O-GlcNAcylation was not sufficient or that other mechanisms are involved. Future work is needed to highlight the contribution of the HBP induction to the hypertrophy in our SKO heart.

Although the precise mechanism remains yet to be completely elucidated, our results support a beneficial cardiac effect of dapagliflozin and therefore are consistent with recent clinical studies. Indeed, the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial has recently demonstrated that empagliflozin strongly decreased both cardiovascular and total mortality (30–40% relative risk reduction) (57) in a large population of patients with T2DM at high cardiovascular risk. This protective effect of the SGLT2 inhibitor occurred very quickly after a few months and was sustained over the 4-year study. In line with our findings, it is tempting to speculate that SGLT2 inhibitors improve cardiac abnormalities at least partly by limiting cardiac glucose overload, HBP activation, and the functional consequences on calcium signaling and aerobic metabolism. Previously, Hong et al. (58) showed that the hypoglycemic SGLT1/SGLT2 inhibitor phlorizin improves the ventricular thickness in nonobese T2DM Akita mice. However, to our knowledge, our study is the first to demonstrate that dapagliflozin might have beneficial cardiac effects by protecting the heart from chronic HBP activation, especially at least through FOXO1 O-GlcNAcylation.

In conclusion, using a unique model for metabolic cardiomyopathy with no lipotoxic features, we highlight that glucotoxicity by itself can trigger cardiac dysfunction and that agents reducing glucose exposure can improve this cardiomyopathy, with a superiority of dapagliflozine over pioglitazone in this specific model.

Article Information

Acknowledgments. The authors thank M. Takahashi, J.-F. Deleuze, and M. Lathrop (Centre de Génotypage–Commissariat à l'Énergie Atomique, Evry, France) for donating the mouse model; C. Dumet, S. Suzanne, S. Lemarchand-Minde (animal facility, L'Institut du Thorax, Nantes, France), and B. Haelewyn (CURB, UNICAEN, Caen, France) for animal care; Dr. Benjamin Lauzier and Dr. Mickael Dergangeon (L'Institut du Thorax, Nantes, France) for fruitful scientific discussions; and Pia Tager (EA 4650, UNICAEN, GIP Cyceron) for assistance during CMR certification exams. The authors also thank the MicroPICell core facility (Structure Fédérative de Recherche François Bonamy, Nantes, France) for microscopy. Lipidomic analyses were performed at Toulouse INSERM MetaToul-Lipidomique Core Facility (MetaboHub ANR-11-INBS-0010).

Funding. This work was supported by grants from INSERM and French associations Aides aux Jeunes Diabétiques, Société Francophone du Diabète, and Fondation de France. X.P. was awarded the European Foundation for the Study of Diabetes/Lilly Research Fellowship Programme 2015.

Duality of Interest. M.J. conducted clinical trials as coinvestigator, provided advisory services, and/or attended conferences as contributor for Lilly, Novo Nordisk, Sanofi, Takeda, Bristol-Myers Squibb, Novartis, AstraZeneca, Boehringer Ingelheim, and Janssen-Cilag. B.C. is taking part in advisory boards for AstraZeneca, Lilly, Sanofi, and Takeda. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. M.J. researched data and wrote the manuscript. B.J., D.M., X.M., A.T., A.A., L.D., G.T., and A.M. researched data. D.M. and B.S. contributed to the scientific discussion and edited the manuscript. C.L.M. and F.C. contributed to scientific discussion. J.M. wrote the manuscript. B.C. contributed to scientific design and wrote the manuscript. X.P. researched data, designed the experiments, and wrote the manuscript. X.P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at the 76th Scientific Sessions of the American Diabetes Association, New Orleans, LA, 10–14 June 2016.

Footnotes

  • This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-0733/-/DC1.

  • Received June 14, 2016.
  • Accepted December 16, 2016.
  • © 2017 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Taegtmeyer H,
    2. McNulty P,
    3. Young ME
    . Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002;105:1727–1733pmid:11940554
    OpenUrlFREE Full Text
  2. ↵
    1. Young ME,
    2. McNulty P,
    3. Taegtmeyer H
    . Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002;105:1861–1870pmid:11956132
    OpenUrlFREE Full Text
  3. ↵
    1. MacDonald MR,
    2. Jhund PS,
    3. Petrie MC, et al
    . Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circ Heart Fail 2008;1:234–241pmid:19808297
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rubler S,
    2. Dlugash J,
    3. Yuceoglu YZ,
    4. Kumral T,
    5. Branwood AW,
    6. Grishman A
    . New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Seferović PM,
    2. Paulus WJ
    . Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Abel ED,
    2. O'Shea KM,
    3. Ramasamy R
    . Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012;32:2068–2076
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Labbé SM,
    2. Grenier-Larouche T,
    3. Noll C, et al
    . Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012;61:2701–2710pmid:23093657
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Drosatos K,
    2. Schulze PC
    . Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 2013;10:109–121
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wende AR,
    2. Abel ED
    . Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801:311–319
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Boudina S,
    2. Bugger H,
    3. Sena S, et al
    . Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009;119:1272–1283
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Zlobine I,
    2. Gopal K,
    3. Ussher JR
    . Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta 2016;1860:1555–1568pmid:26899197
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kolwicz SC Jr.,
    2. Tian R
    . Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 2011;90:194–201pmid:21502371
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Mazumder PK,
    2. O’Neill BT,
    3. Roberts MW, et al
    . Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366–2374pmid:15331547
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Taegtmeyer H,
    2. Beauloye C,
    3. Harmancey R,
    4. Hue L
    . Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013;305:H1693–H1697
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Montaigne D,
    2. Marechal X,
    3. Coisne A, et al
    . Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 2014;130:554–564pmid:24928681
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Magré J,
    2. Delépine M,
    3. Khallouf E, et al.; BSCL Working Group
    . Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001;28:365–370pmid:11479539
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Garg A.
    Clinical review. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011;96:3313–3325
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Lupsa BC,
    2. Sachdev V,
    3. Lungu AO,
    4. Rosing DR,
    5. Gorden P
    . Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine (Baltimore) 2010;89:245–250
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Rheuban KS,
    2. Blizzard RM,
    3. Parker MA,
    4. Carter T,
    5. Wilson T,
    6. Gutgesell HP
    . Hypertrophic cardiomyopathy in total lipodystrophy. J Pediatr 1986;109:301–302pmid:3734966
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Jeninga EH,
    2. de Vroede M,
    3. Hamers N, et al
    . A patient with congenital generalized lipodystrophy due to a novel mutation in BSCL2: indications for secondary mitochondrial dysfunction. JIMD Rep 2012;4:47–54pmid:23430896
    OpenUrlPubMed
  21. ↵
    1. Nelson MD,
    2. Victor RG,
    3. Szczepaniak EW,
    4. Simha V,
    5. Garg A,
    6. Szczepaniak LS
    . Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 2013;112:1019–1024
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cui X,
    2. Wang Y,
    3. Tang Y, et al
    . Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet 2011;20:3022–3030
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Chen W,
    2. Chang B,
    3. Saha P, et al
    . Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol 2012;32:1099–1111
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Prieur X,
    2. Dollet L,
    3. Takahashi M, et al
    . Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia 2013;56:1813-1825
    OpenUrlCrossRefPubMed
  25. ↵
    1. Royer A,
    2. van Veen TA,
    3. Le Bouter S, et al
    . Mouse model of SCN5A-linked hereditary Lenègre’s disease: age-related conduction slowing and myocardial fibrosis. Circulation 2005;111:1738–1746pmid:15809371
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Joubert M,
    2. Hardouin J,
    3. Legallois D, et al
    . Effects of glycaemic variability on cardiac remodelling after reperfused myocardial infarction: evaluation of streptozotocin-induced diabetic Wistar rats using cardiac magnetic resonance imaging. Diabetes Metab 2016;42:342–350pmid:26971835
    OpenUrlPubMed
  27. ↵
    1. Armbrecht JJ,
    2. Buxton DB,
    3. Schelbert HR
    . Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 1990;81:1594–1605pmid:2110037
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Bugger H,
    2. Boudina S,
    3. Hu XX, et al
    . Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008;57:2924–2932
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Galgani JE,
    2. Vasquez K,
    3. Watkins G, et al
    . Enhanced skeletal muscle lipid oxidative efficiency in insulin-resistant vs insulin-sensitive nondiabetic, nonobese humans. J Clin Endocrinol Metab 2013;98:E646–E653
    OpenUrlCrossRefPubMed
  30. ↵
    1. Montaigne D,
    2. Marechal X,
    3. Baccouch R, et al
    . Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol Appl Pharmacol 2010;244:300–307
    OpenUrlCrossRefPubMed
  31. ↵
    1. Brown MA,
    2. Myears DW,
    3. Bergmann SR
    . Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. J Nucl Med 1989;30:187–193pmid:2786932
    OpenUrlAbstract/FREE Full Text
    1. Brown MA,
    2. Myears DW,
    3. Bergmann SR
    . Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol 1988;12:1054–1063
    OpenUrlCrossRefPubMed
  32. ↵
    1. Welch MJ,
    2. Lewis JS,
    3. Kim J, et al
    . Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. J Nucl Med 2006;47:689–697
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Issad T,
    2. Masson E,
    3. Pagesy P
    . O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab 2010;36:423–435pmid:21074472
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. van den Brom CE,
    2. Huisman MC,
    3. Vlasblom R, et al
    . Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 2009;8:39pmid:19624828
    OpenUrlCrossRefPubMed
  35. ↵
    1. Chen W,
    2. Zhou H,
    3. Saha P,
    4. Li L,
    5. Chan L
    . Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology 2014;155:4215–4225pmid:25093462
    OpenUrlCrossRefPubMed
  36. ↵
    1. Cui X,
    2. Wang Y,
    3. Tang Y, et al
    . Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet 2011;20:3022–3030
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Kaczmarczyk SJ,
    2. Andrikopoulos S,
    3. Favaloro J, et al
    . Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 2003;31:449–459
    OpenUrlAbstract
  38. ↵
    1. Shao D,
    2. Tian R
    . Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol 2015;6:331–351pmid:26756635
    OpenUrlCrossRefPubMed
  39. ↵
    1. Grassi I,
    2. Nanni C,
    3. Allegri V, et al
    . The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging 2012;2:33–47
    OpenUrlPubMed
  40. ↵
    1. Bugger H,
    2. Abel ED
    . Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009;2:454–466
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Shoghi KI,
    2. Gropler RJ,
    3. Sharp T, et al
    . Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med 2008;49:1320–1327
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Dolinsky VW,
    2. Dyck JR
    . Role of AMP-activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 2006;291:H2557–H2569
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Dassanayaka S,
    2. Jones SP
    . O-GlcNAc and the cardiovascular system. Pharmacol Ther 2014;142:62–71pmid:24287310
    OpenUrlCrossRefPubMed
  44. ↵
    1. Marsh SA,
    2. Dell’Italia LJ,
    3. Chatham JC
    . Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 2011;40:819–828pmid:20676904
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Young ME,
    2. Yan J,
    3. Razeghi P, et al
    . Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio 2007;1:251–262
    OpenUrlPubMed
  46. ↵
    1. Fricovsky ES,
    2. Suarez J,
    3. Ihm SH, et al
    . Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 2012;303:R689–R699
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Banerjee PS,
    2. Ma J, and
    3. Hart GW
    . Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc Natl Acad Sci U S A 2015;112:6050–6055
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Kuo M,
    2. Zilberfarb V,
    3. Gangneux N,
    4. Christeff N,
    5. Issad T
    . O-GlcNAc modification of FoxO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon? Biochimie 2008;90:679–685pmid:18359296
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Issad T,
    2. Kuo M
    . O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008;19:380–389pmid:18929495
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Battiprolu PK,
    2. Hojayev B,
    3. Jiang N, et al
    . Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012;122:1109–1118
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Chang CS,
    2. Tsai PJ,
    3. Sung JM,
    4. Chen JY,
    5. Ho LC,
    6. Pandya K,
    7. Maeda N, and
    8. Tsai YS
    . Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol 2014;184:442–453
    OpenUrl
  52. ↵
    1. Mannucci E,
    2. Monami M,
    3. Lamanna C,
    4. Gensini GF,
    5. Marchionni N
    . Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221–1238pmid:18505403
    OpenUrlPubMedWeb of Science
  53. ↵
    1. Heerspink HJ,
    2. Perkins BA,
    3. Fitchett DH,
    4. Husain M,
    5. Cherney DZ
    . Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016;134:752–772pmid:27470878
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Ferrannini E,
    2. Mark M,
    3. Mayoux E
    . CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 2016;39:1108–1114pmid:27289126
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Mailleux F,
    2. Gélinas R,
    3. Beauloye C,
    4. Horman S,
    5. Bertrand L
    . O-GlcNAcylation, enemy or ally during cardiac hypertrophy development? Biochim Biophys Acta 2016;1862:2232–2243
    OpenUrl
  56. ↵
    1. Zinman B,
    2. Wanner C,
    3. Lachin JM, et al.; EMPA-REG OUTCOME Investigators
    . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
    OpenUrlCrossRefPubMed
  57. ↵
    1. Hong EG,
    2. Jung DY,
    3. Ko HJ, et al
    . Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007;293:E1687–E1696
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 66 (4)

In this Issue

April 2017, 66(4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Michael Joubert, Benoît Jagu, David Montaigne, Xavier Marechal, Angela Tesse, Audrey Ayer, Lucile Dollet, Cédric Le May, Gilles Toumaniantz, Alain Manrique, Flavien Charpentier, Bart Staels, Jocelyne Magré, Bertrand Cariou, Xavier Prieur
Diabetes Apr 2017, 66 (4) 1030-1040; DOI: 10.2337/db16-0733

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Michael Joubert, Benoît Jagu, David Montaigne, Xavier Marechal, Angela Tesse, Audrey Ayer, Lucile Dollet, Cédric Le May, Gilles Toumaniantz, Alain Manrique, Flavien Charpentier, Bart Staels, Jocelyne Magré, Bertrand Cariou, Xavier Prieur
Diabetes Apr 2017, 66 (4) 1030-1040; DOI: 10.2337/db16-0733
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes
  • Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker–Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19
  • Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
Show more Complications

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.